Table 3.
Characteristics of studies reporting person-level data
| Author, Year | Disease | Number enrolled (analysed) | Intervention | Comparator | Cross-over periods | Total intervention duration | Outcome measures per period |
| Studies with reanalysable person-level outcomes | |||||||
| Camfield, 1996 | Mental retardation with fragmented sleep | 6 (6) | Melatonin | Placebo | 7 | 10 weeks | 14 |
| Hinderer, 1990 |
Traumatic spinal cord injury | 5 (5) | Baclofen | Placebo | 3 | 9 weeks | 2 |
| Langer, 1993 |
Gastro-oesophageal reflux | 2 (2) | Cisapride | Placebo | 3 | 6 weeks | 5 |
| Lashner, 1990 |
Ulcerative colitis | 7 (6) | Nicotine | Placebo | 4 | 8 weeks | 1 |
| Maier, 1994 |
Chronic depression | 10 (9) | Sulpiride | Placebo | 4 | 28 weeks | 42 |
| Mandelcorn, 2004 | Brain injury | 4 (4) | Ondansetron | Placebo | 4 | 5 weeks | 1 |
| McQuay, 1994 |
Neuropathic pain | 19 (19) | Dextromethorphan | Placebo | 5 | 20 days | 1 |
| Miyazaki, 1995 | Unstable angina | 22 (22) | Isosorbide dinitrate | Isosorbide dinitrate: intermittent injection | 3 | 9 days | 6 |
| Nathan, 2006 |
Paediatric brain tumour | 12 (7) | Ondansetron and metopimazine |
Ondansetron and placebo | Unclear | 189 days | Unclear |
| Parodi, 1979 |
Unstable angina | 12 (12) | Verapamil | Placebo | 4 | 10 days | Unclear |
| Parodi, 1986 |
Unstable angina | 10 (10) | Verapamil | Propranolol, placebo | 8 | 18 days | Unclear |
| Tison, 2012 |
Levodopa-induced dyskinesia in patients with Parkinson’s disease | 10 (10) | Simvastatin | Placebo | 6 | 96 days | 1 |
| Studies with re-analyzable person-level treatment effects | |||||||
| Emmanuel, 2012 |
Chronic intestinal pseudo-obstruction | 7 (4) | Prucalopride | Placebo | 16 | 48 weeks | 21 |
| Haas, 2004 |
Chronic tension type and migraine headache | 39 (16) | Dextroamphetamine | Equi-stimulatory caffeine | 8 | 20 days | 20 |
| Jaeschke, 1991 |
Fibromyalgia | 22 (23) | Amitriptyline | Placebo | 6 | 12 weeks | 2 |
| Johannessen, 1992 |
Dyspepsia | 68 (46) | Cimetidine | Placebo | 12 | 184 days | 15 |
| Lipka, 2017 |
Autoimmune myasthenia gravis | 4 (4) | Ephedrine | Placebo | 4 | 6 weeks | 1 |
| Mahon, 1996 |
Irreversible chronic airflow limitation | 16 (14) | Theophylline | Placebo | 8 | 73 days | 1 |
| March, 1994 |
Osteoarthritis | 25 (15) | Diclofenac | Paracetamol | 6 | 12 weeks | 14 |
| Patel, 1991 |
Non-reversible chronic airflow limitation | 26 (18) | Ipratropium bromide/theophylline /salbutamol /beclomethasone |
Placebo | 6 | 6 weeks | Unclear |
| Wallace, 1994 |
Attention deficit hyperactivity disorder | 11 (7) | Methylphenidate | Placebo | 14 | 14 days | 1 |
| Woodfield, 2005 |
Skeletal muscle cramps | 13 | Quinine | Placebo | 6 | 14 weeks | 2 |
| Zucker, 2006 |
Fibromyalgia | 58 | Amitriptyline and placebo | Amitriptyline and fluoxetine combination | 6 | 36 weeks | 1 |
| Study with both person-level data | |||||||
| Pereira, 1995 |
Atrial fibrillation/deep venous thrombosis | 7 | Generic warfarin | Coumadin | 10 | 30 weeks | 2 |
| Joy, 2014 |
Statin-related myalgia | 8 (7) | Statin | Placebo | 6 | 33 weeks | 3 |
| Study with insufficiently reported person-level data | |||||||
| Person-level outcome data | |||||||
| Denburg, 1994 |
Systemic lupus erythematosus | 10 | Prednisone | Placebo | 6 | 30 weeks | 1 |
| Mitchel, 2015 |
Fatigue in advanced cancer | 43 (33) | Methylphenidate | Placebo | 6 | 18 days | 6 |
| Nikles, 2000 |
Osteoarthritis | 14 | Ibuprofen | Paracetamol; placebo | 6 | 12 weeks | 14 |
| Nikles, 2015 |
Dry mouth in advanced cancer | 17 (4) | Pilocarpine | Placebo | 6 | 18 days | 6 |
| Nikles, 2017 |
Acquired brain injury | 53 (38) | Nervous system stimulants | Placebo | 6 | 18 days | 6 |
| Reitberg, 2002 |
Allergic rhinitis | 36 | Loratadine and chlorpheniramine maleate |
loratadine with placebo | 8 | 32 days | 4 |
| Sheather-Reid, 1998 |
Chronic pain | 8 | Ibuprofen/codeine | Placebo | 6 | 12 weeks | 14 |
| Person-level treatment effects | |||||||
| Huber, 2007 |
Juvenile idiopathic arthritis | 6 | Amitriptyline | Placebo | 6 | 17 weeks | 12 |
| Privitera, 1994 |
Partial seizure | 16 | Dezinamide | Placebo | 6 | 35 weeks | 6 |
| Wegman, 2003 |
Osteoarthritis | 13 | Paracetamol | Non-steroidal anti-inflammatory drugs | 10 | 20 weeks | 14 |
| Wegman, 2005 |
Regular temazepam users | 15 | Temazepam | Placebo | 10 | 10 weeks | 7 |